Antisense Therapeutics has been granted a patent for a method to treat muscular dystrophy by periodically administering a specific oligonucleotide. This treatment aims to improve or maintain limb muscle function and strength in affected individuals, utilizing a unique chemical structure and composition. GlobalData’s report on Antisense Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Antisense Therapeutics, Nucleic acid active pharmaceutical ingredient was a key innovation area identified from patents. Antisense Therapeutics's grant share as of June 2024 was 48%. Grant share is based on the ratio of number of grants to total number of patents.
Method for treating muscular dystrophy using oligonucleotides
The granted patent US11976281B2 outlines a method aimed at enhancing limb muscle function or strength, or delaying the decline in muscle function in subjects diagnosed with muscular dystrophy (MD). The method involves the periodic administration of a pharmaceutical composition that includes a specific oligonucleotide sequence (SEQ ID NO: 1) combined with a pharmaceutically acceptable carrier. This oligonucleotide is characterized by unique structural features, including O,O-linked phosphorothioate diester linkages and specific modifications to the nucleotides. The therapeutically effective dosage is specified to be between 25 mg to 100 mg, with administration frequency ranging from once to three times per week or month.
The patent further details the types of muscular dystrophy applicable to this method, including Duchenne muscular dystrophy (DMD), Becker muscular dystrophy (BMD), and others, particularly those involving mutations in the dystrophin gene. It also specifies that the method can be used in conjunction with corticosteroid treatments, such as prednisolone or deflazacort, at reduced dosages compared to standard treatments. The claims include various dosing regimens, emphasizing flexibility in administration while maintaining therapeutic efficacy. This patent represents a potential advancement in the treatment of muscular dystrophy, focusing on improving muscle function and strength in affected individuals.
To know more about GlobalData’s detailed insights on Antisense Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
